Immune-Related Adverse Events in the Older Adult with Cancer Receiving Immune Checkpoint Inhibitor Therapy

OBJECTIVE: Older adults with cancer (OAC) may be at elevated risk for immune-related adverse events (irAEs) during immune checkpoint inhibitor (ICI) therapy due to the normal organ function changes of aging, as well as related to a higher prevalence of comorbid conditions compared to younger patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Biniakewitz, Matthew D., Kasler, Mary Kate, Fessele, Kristen L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7785075/
https://www.ncbi.nlm.nih.gov/pubmed/33426185
http://dx.doi.org/10.4103/apjon.apjon_48_20

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7785075/
https://www.ncbi.nlm.nih.gov/pubmed/33426185
http://dx.doi.org/10.4103/apjon.apjon_48_20

Ejemplares similares